Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead Sciences Inc

Looking for Value Stocks to Add to Your Portfolio? Here are 5 For Your List

Heightened inflationary pressure, deepening supply chain disruptions, and the possibility of aggressive interest rate hikes later this year have fostered a volatile stock market. Because these factors are not expected to abate anytime soon, we think investors looking to generate solid long-term returns could consider betting on the stocks of…

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy

NRx Pharmaceuticals Inc (NASDAQ:NRXP) has filed a new Breakthrough Therapy designation request with the FDA for Zyesami focused on a subgroup of critical COVID-19 patients. The subgroup includes patients who were also treated with Gilead Sciences Inc's (NASDAQ:GILD) Veklury (remdesivir) in addition to aviptadil or placebo. The request includes safety data on approximately 750 patients…

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant

The FDA said that the currently authorized 500mg dose of GlaxoSmithKline Plc (NYSE:GSK) and Vir Biotechnology Inc's (NASDAQ:VIR) COVID-19 antibody therapy is unlikely to be effective against the omicron BA.2 variant. The agency updated its website to exclude sotrovimab use in geographic regions where the infection is likely caused by the omicron BA.2 variant. GSK…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Sciences' Trodelvy Study In Breast Cancer Meets Primary Endpoint

Gilead Sciences Inc (NASDAQ: GILD) announced results from the Phase 3 TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer.

Gilead Hit By FDA Complete Response Letter For Lenacapavir In HIV Infection

The FDA has issued a complete response letter (CRL) for Gilead Sciences Inc's (NASDAQ:GILD) application for lenacapavir for heavily treated multi-drug resistant (MDR) HIV-1 infection. Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor. In the CRL, the FDA has cited Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of lenacapavir with the…

Gilead's Lenacapavir Shows Sustained Efficacy In Pretreated HIV Patients

Gilead Sciences Inc (NASDAQ: GILD)

Gilead Shares Updated Data From Remdesivir Study In Pediatric COVID-19 Patients

Gilead Sciences Inc (NASDAQ: GILD)

inkl

Read news from The Economist, FT, and more,
with one subscription

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead's Remdesivir Retains Antiviral Activity Against Several COVID-19 Variants, Including Omicron

Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) has

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GSK To Get $1.25B As Settlement For HIV Treatment Drug Patent Row With Gilead

GlaxoSmithKline plc (NYSE: GSK) has settled a patent dispute between ViiV Healthcare and Gilead Sciences Inc (NASDAQ: GILD).

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates

Gilead Sciences Inc (NASDAQ: GILD) posted

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Alleges Counterfeiting Network Sold Fake HIV Drugs

Gilead Sciences Inc (NASDAQ: GILD) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years.

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Withdraws Use Of Zydelig In Two Forms Of Blood Cancer In US

Gilead Sciences Inc (NASDAQ: GILD) recently notified the FDA of its decision to

1 2 3 4 5

Organisations

Gilead Sciences Inc

Eli Lilly And Co

GlaxoSmithKline Plc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

236,818 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play